News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Hyung L. Kim, MD

Articles by Hyung L. Kim, MD

Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics

ByJun Gong, MD,Edwin M. Posadas, MD,Neil Bhowmick, PhD,Hyung L. Kim, MD,Timothy J. Daskivich, MD,Amit Gupta, MD,Howard M. Sandler, MD,Mitchell Kamrava, MD,Zachary S. Zumsteg, MD,Stephen J. Freedland, MD,Robert A. Figlin, MD

March 17th 2021

Experts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.

Latest Updated Articles

Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics
March 17th 2021

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC

Achieving a “Functional Cure” With Multiple Myeloma Therapy